Novo Nordisk (NVO) Price & Analysis

Compare

10,769 Followers

NVO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$46.90 - $139.74

Previous CloseN/A

Volume3.65M

Average Volume (3M)15.45M

Market Cap

$212.60B

Enterprise Value$321.61B

Total Cash (Recent Filing)$41.55B

Total Debt (Recent Filing)$118.72B

Price to Earnings (P/E)14.3

Beta1.02

Next Earnings

Aug 06, 2025

EPS Estimate

0.92

Last Dividend Ex-Date

Mar 31, 2025

Dividend Yield3.34%

Share Statistics

EPS (TTM)0.99

Shares Outstanding3,390,128,000

10 Day Avg. Volume31,566,058

30 Day Avg. Volume15,453,901

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.51

Enterprise Value/Revenue1.06

Enterprise Value/Gross Profit1.26

Enterprise Value/Ebitda2.09

Forecast

1Y Price Target

$73.00

Price Target Upside51.48% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Leadership ChangeA new CEO, Mike Doustdar, has been appointed, potentially bringing a global perspective and re-energizing the struggling strategy.

Pipeline InnovationNovo Nordisk is committed to driving the next wave of pipeline innovation.

Product DevelopmentNovo Nordisk is pushing ahead with high-dose oral semaglutide for the treatment of obesity as an option for patients who may not want to use injectables.

Bears Say

Competitive PressureOzempic's US underperformance is accentuated by competition in the US, leading to weaker-than-expected sales.

Market CompetitivenessNovo Nordisk shares are expected to remain less competitive versus other peers in the cardiometabolic market.

Sales PerformanceLower Wegovy sales expectations were specifically impacted by continued/higher-than-expected compounding in the US market and slower-than-expected market expansion.

Novo Nordisk News

Novo Nordisk downgraded to Neutral from Buy at UBS

UBS downgraded Novo Nordisk (NVO) to Neutral from Buy with a price target of DKK 340, down from...

12h ago

NVO

Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect

Hims & Hers Health ($HIMS) is scheduled to announce its results for the second quarter of 2025 after...

1d ago

NVO

HIMS

Options Volatility and Implied Earnings Moves This Week, August 04 – August 08, 2025

This week, several major companies will be reporting earnings. Among them are Advanced Micro Devices (AMD), Palantir Technologies...

1d ago

Lilly, Novo rally after report of Medicare weight loss coverage

Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) are moving higher after the Washington Post reported that...

4d ago

LLY

NVO

Unusually active option classes on open August 1st

Unusual total active option classes on open include: ARK Genomic Revolution Multi Sector ETF (ARKG), Direxion Daily Small...

4d ago

AUR

NVO

Medicare to cover weight loss drugs in experiment, Washington Post says

Under a Trump administration proposal, state Medicaid programs and Medicare Part D insurance plans will be able to...

4d ago

LLY

NVO

Novo Nordisk removed from European Conviction List at Goldman Sachs

Goldman Sachs analysts removed Novo Nordisk (NVO) from its European Conviction List as part of its monthly update....

5d ago

NVO

Trump posts letters calling on drug company CEOs to lower prices

Letters were sent to the CEOs of AbbVie (ABBV), Boehringer Ingelheim, Bristol Myers Squibb (BMY), Novartis (NVS), Gilead...

5d ago

AZN

BMY

Novo Nordisk downgraded to Hold from Buy at HSBC

HSBC downgraded Novo Nordisk (NVO) to Hold from Buy with a $57 price target The firm says its...

5d ago

NVO

Is Novo Nordisk Stock a Falling Knife? Here’s What This Top Investor Thinks

Novo Nordisk (NYSE:NVO) was in the news quite a bit this week, though not for reasons the firm...

6d ago

NVO

NYSE

Novo Nordisk price target lowered to DKK 500 from DKK 650 at JPMorgan

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 500 from DKK 650 and keeps...

6d ago

NVO

Eli Lilly Stock (LLY) Will Benefit from ‘Onshoring Boom,’ Says BMO Capital Markets

The company also has a promising Alzheimer’s treatment. ...

6d ago

BMO

LLY

Notable open interest changes for July 30th

Tuesday’s total option volume of 54.6 million contracts resulted in net open interest growth of 6.05 million calls...

6d ago

AMD

NVO

Novo Nordisk downgraded to Neutral from Buy at BofA

BofA downgraded Novo Nordisk (NVO) to Neutral from Buy with a price target of DKK 375, down from...

6d ago

NVO

NVO FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was $46.90 and its highest was $139.74 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is $212.60B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Aug 06, 2025 which is tomorrow.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on May 07, 2025. The company reported $0.995 earnings per share for the quarter, beating the consensus estimate of $0.915 by $0.08.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk pays a Semiannually dividend of $1.099 which represents an annual dividend yield of 3.34%. See more information on Novo Nordisk dividends here

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.92.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of $0.995 in its last earnings report, beating expectations of $0.915. Following the earnings report the stock price went up 1.901%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in NVO

Novo Nordisk Stock Smart Score

Underperform

Fundamentals

Return on Equity

87.53%

Trailing 12-Months

Asset Growth

63.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novo Nordisk

Novo Nordisk (NVO) is a global healthcare company headquartered in Denmark, specializing in the development, production, and marketing of pharmaceutical products and services. The company is a leader in diabetes care, offering a comprehensive portfolio of insulin and GLP-1 receptor agonists. In addition to diabetes care, Novo Nordisk has a robust presence in other therapeutic areas, including obesity care, hemophilia, growth hormone therapy, and hormone replacement therapy. The company is committed to advancing medical treatments and improving quality of life for patients worldwide.

Novo Nordisk (NVO) Earnings & Revenues

NVO Earnings Data >

NVO Company Deck

NVO Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong sales and profit growth, increased patient reach, and significant regulatory milestones. However, challenges with compounded GLP-1 drugs in the U.S., increased carbon emissions, and a reduced full-year outlook due to lower-than-planned penetration of branded GLP-1 treatments were notable lowlights.Read More>

NVO Stock 12 Month Forecast

Average Price Target

$73.00

▲(51.48%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"54":"$54","99":"$99","144":"$144","76.5":"$76.5","121.5":"$121.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$73.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[54,76.5,99,121.5,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.82,71.37230769230769,72.92461538461538,74.47692307692307,76.02923076923076,77.58153846153846,79.13384615384615,80.68615384615384,82.23846153846154,83.79076923076923,85.34307692307692,86.89538461538461,88.44769230769231,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.82,70.06461538461538,70.30923076923077,70.55384615384615,70.79846153846154,71.04307692307692,71.28769230769231,71.53230769230768,71.77692307692307,72.02153846153846,72.26615384615384,72.51076923076923,72.75538461538461,{"y":73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.82,68.67999999999999,67.53999999999999,66.39999999999999,65.25999999999999,64.11999999999999,62.98,61.839999999999996,60.699999999999996,59.56,58.42,57.28,56.14,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":143.39,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >